Results 211 to 220 of about 8,527,959 (316)

From scarring to healing: Emerging regenerative therapies for pulmonary fibrosis using MSCs and exosomes

open access: yesClinical and Translational Discovery, Volume 6, Issue 4, August 2026.
MSCs exert anti‐inflammatory, anti‐fibrotic and regenerative effects in pulmonary fibrosis. MSC‐derived exosomes reproduce many therapeutic benefits of parental MSCs. Preconditioning and genetic modification improve MSC therapeutic performance. Current preclinical and clinical evidence supports the translational potential of MSC‐based therapies ...
Hajar Nasiri   +8 more
wiley   +1 more source

Impact of Infratemporal Fossa Clearance on Survival in Advanced Buccal Mucosa Cancers

open access: yesHead &Neck, Volume 48, Issue 8, Page 2135-2143, August 2026.
ABSTRACT Introduction Buccal mucosa cancers are the most prevalent oral cavity cancers in South Asia, often attributed to widespread tobacco use. The current NCCN guidelines generally advise against primary surgery for locally very advanced (cT4b) buccal cancers involving the masticatory space and infratemporal fossa (ITF).
Sudhir Nair   +11 more
wiley   +1 more source

De novo or Salvage? Nucleotide Availability as a Driver of Bacterial Adaptation and Virulence

open access: yesMicrobiologyOpen, Volume 15, Issue 4, August 2026.
Bacterial pathogens survive in different host environments by switching between making nucleotides by de novo synthesis and scavenging them from the host. This flexibility supports growth and virulence making nucleotide metabolism an attractive therapeutic target.
Riya Joshi   +2 more
wiley   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

open access: yesInternational Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins   +3 more
wiley   +1 more source

Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma

open access: yesInternational Journal of Cancer, Volume 159, Issue 2, Page 501-515, 15 July 2026.
What's new? Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor survival and variable response to perioperative chemotherapy. Although histopathological features correlate with outcomes, the relationship specifically between adherens junction (AJ) protein expression and treatment response in EAC remains uncertain.
Bastian Grothey   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy